To unlock the potential of drugging undruggable targets through protein degraders and RNA targeted drugs, Axcelead offers comprehensive supports on your drug discovery journey by utilizing dedicated new chemical modality libraries and assays as well as our expertise and experience in drug discovery which are backed by a proven track record.
Solutions for Protein Degraders
Axcelead offers a full suite of platforms for hit and lead exploration of RNA targeted drugs. For example, we have successfully identified hit compounds that bound to FMN riboswitch RNA by using our diverse and general RNA focused libraries. We identified several potent hit compounds by utilizing Affinity Selection Mass Spectrometry (AS-MS) method. Cocrystal structural analysis demonstrated the binding mode of a small molecule compound.
Protein degrader platform
Solutions for RNA Targeted Drugs
Axcelead offers a full suite of platforms for hit and lead exploration of RNA targeted drugs. For example, we have successfully identified hit compounds that bound to FMN riboswitch RNA by using our diverse and general RNA focused libraries. We identified several potent hit compounds by utilizing Affinity Selection Mass Spectrometry (AS-MS) method. Cocrystal structural analysis of compounds demonstrated the binding mode of our hit compounds.
Track Records: 15, including HTS and lead discovery
Axcelead is also involved in joint projects with xFOREST Therapeutics and Kyowa Kirin Co., Ltd.
RNA targeted drug platform
RNA focused library (general)
- 6,400 compounds selected from whole Axcelead library collection of 1.5 million compounds
- Prioritized by physicochemical characteristics relevant to RNA binding agents and drug discovery
- Superior hit rates compared to other in-house libraries for RNA targets
RNA targeted drug exploration using HT-ASMS
